Dr. Narain: SLE flare risk w/ HCQ tapering/reducing dose vs maintaining. Retinopathy risk: 💎doubles every 5 yrs of use 💎^ w/ ^ dosing per ABW 💎^ w/ IBW in dose-response manner 💎independent risk factors: cumulative HCQ use, duration of use, CKD, Asian decent #RNL2022 @RheumNow https://t.co/lgMNEmQEhl